Unichem Laboratories Downgraded to Strong Sell Amid Financial and Operational Challenges

Financial Trend Deterioration Triggers Downgrade

One of the primary drivers behind the downgrade is the marked decline in Unichem’s financial trend. The company’s financial trend score has shifted from flat to negative, with the latest quarter ending December 2025 revealing significant setbacks. Profit Before Tax excluding Other Income (PBT less OI) plunged by 77.2% to ₹6.11 crores compared to the previous four-quarter average, signalling a sharp contraction in core profitability. Similarly, Profit After Tax (PAT) fell by 56.0% to ₹16.13 crores, underscoring the strain on bottom-line performance.

Adding to the pressure, interest expenses surged by 30.5% over the last six months to ₹15.66 crores, reflecting increased borrowing costs. The company’s debt-equity ratio, while moderate at 0.21 times, is accompanied by a concerning Debt to EBITDA ratio of 4.87 times, indicating a low ability to service debt effectively. Net sales for the quarter were also at a low ₹521.17 crores, further highlighting operational challenges.

Despite these negatives, Unichem’s Return on Capital Employed (ROCE) for the half-year stood at a relatively healthy 6.30%, and quarterly Earnings Per Share (EPS) reached ₹37.54, the highest recorded. However, these positives have been insufficient to offset the broader financial deterioration.

Valuation Grade Improves but Remains Cautious

While the financial trend has worsened, Unichem’s valuation grade has improved from very attractive to attractive. The company currently trades at a price-to-earnings (PE) ratio of 26.43, which is lower than many of its pharmaceutical peers such as Gland Pharma (PE 35.14) and J B Chemicals (PE 39.34). The Price to Book Value stands at 1.14, and the Enterprise Value to EBITDA ratio is 14.20, indicating a relatively reasonable valuation compared to sector averages.

Moreover, the PEG ratio of 0.89 suggests that the stock is undervalued relative to its earnings growth potential, with profits rising by 29.9% over the past year despite a 45.68% decline in share price. The company’s ROCE of 4.9% and ROE of 6.03% further support the notion of an attractive valuation, although these returns remain modest in absolute terms.

Nonetheless, the valuation improvement has not been sufficient to counterbalance the negative financial momentum and operational risks, leading to a cautious stance from analysts.

Quality Assessment Reflects Mixed Signals

Unichem Laboratories’ quality parameters present a mixed picture. On the positive side, the company has demonstrated healthy long-term growth in operating profit, with an annualised growth rate of 148.09%. This indicates operational resilience and potential for future expansion. However, the average Return on Equity (ROE) over recent periods is a low 1.44%, signalling limited profitability per unit of shareholder funds.

Additionally, the company’s non-operating income constitutes a significant 65.88% of Profit Before Tax, raising questions about the sustainability of earnings from core operations. The stock’s 52-week price range between ₹362.10 and ₹757.40, with a current price of ₹394.20, reflects considerable volatility and investor uncertainty.

Technical Indicators and Market Performance

From a technical perspective, Unichem’s stock has underperformed key benchmarks over multiple time horizons. The stock’s one-year return is a negative 45.68%, starkly contrasting with the Sensex’s 7.07% gain over the same period. Even over three and five years, the stock’s returns of 26.87% and 23.40% lag behind the Sensex’s 38.13% and 64.75%, respectively.

Recent trading sessions have been volatile, with the stock falling 8.34% on 9 February 2026, closing at ₹394.20 after hitting a high of ₹434.65. This price action, combined with weak financial results and elevated debt servicing costs, has contributed to a downgrade in technical scores and overall Mojo Grade from Sell to Strong Sell, with a current Mojo Score of 28.0.

Sector Context and Peer Comparison

Within the Pharmaceuticals & Biotechnology sector, Unichem Laboratories faces stiff competition from companies with stronger financials and more robust growth trajectories. Peers such as Gland Pharma and J B Chemicals & Pharmaceuticals are currently rated as very expensive but have demonstrated higher profitability and growth metrics. Unichem’s attractive valuation may appeal to value investors, but the company’s weak financial trend and technical indicators caution against aggressive accumulation at this stage.

Furthermore, the company’s promoter holding remains majority, which provides some stability, but the elevated interest costs and declining profitability raise concerns about capital allocation and operational efficiency going forward.

Conclusion: Downgrade Reflects Heightened Risks

In summary, the downgrade of Unichem Laboratories Ltd to Strong Sell is driven by a combination of deteriorating financial trends, including sharp declines in profitability and rising interest expenses, alongside modest improvements in valuation metrics that remain overshadowed by operational challenges. The company’s technical performance and market returns have lagged significantly behind benchmarks, reinforcing the cautious stance.

Investors should weigh the risks of continued financial underperformance and debt servicing pressures against the company’s attractive valuation and pockets of operational strength. Until there is clear evidence of a turnaround in earnings quality and financial stability, the Strong Sell rating reflects the heightened risk profile of Unichem Laboratories within the Pharmaceuticals & Biotechnology sector.

Unlock special upgrade rates for a limited period. Start Saving Now →